Skip to main content

Table 1 Baseline characteristics of the study population

From: Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis

  Total study population (n = 772) non-SDFR group (n = 623) SDFR group (n = 149)
Age (years), mean (SD) 58.0 (15.4) 56.6 (15.2) 64.0 (14.9)
Females, n (%) 528 (68.4) 435 (70.7) 88 (59.1)
ACPA positivity+ n (%) 348 (45.1) 333 (54.1) 15 (10.1)
Symptom duration at diagnosis+
(≤ 12 vs > 12 weeks), n (%)
257 (33.5) 207 (33.2) 50 (33.6)
DAS at baseline+, med (IQR) 3.10 (2.52–3.72) 3.10 (2.51–3.69) 3.10 (2.55–3.91)
SJC at baseline+, (0–44), med (IQR) 6 (3–11) 6 (3–11) 8 (4–13)
TJC at baseline+, (0–53), med (IQR) 6 (4–9) 6 (4–10) 6 (4–9)
ESR+ (mm/h), med (IQR) 29 (14–45) 29 (14–45) 29 (14–47)
VAS+ (0–100 mm), med (IQR) 40 (20–60) 41 (20–60) 38 (20–60)
  1. Legend: Baseline characteristics of the patients with RA in the total study population and subgroups according to achievement of sustained DMARD-free remission (SDFR) during 7 years of follow-up. +ACPA status was missing in 24 patients. Symptom duration was missing in 50 patients. DAS at baseline was missing in 124 patients. DAS components SJC, TJC, ESR, and VAS were missing in 29, 124, 8, and 101 patients
  2. DAS disease activity score based on swollen joint count (44 joints), tender joint count (53 joints), ESR, and pain; SJC swollen joint count; TJC tender joint count, ESR estimated sedimentation rate; VAS visual analog scale, ACPA anti-citrullinated protein antibody